Molecular basis of mantle cell lymphoma, British Journal of Haematology, vol.10, issue.2, pp.130-140, 2004. ,
DOI : 10.1046/j.1365-2141.1996.5421085.x
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Lyon: International agency for research on cancer, 2008. ,
How I treat mantle cell lymphoma, Blood, vol.114, issue.8, pp.1469-1476, 2009. ,
DOI : 10.1182/blood-2009-02-179739
Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways, Leukemia, vol.32, issue.1, pp.13-21, 2009. ,
DOI : 10.1016/j.cellsig.2009.03.009
Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma, Blood, vol.111, issue.10, pp.5142-5151, 2008. ,
DOI : 10.1182/blood-2007-07-103481
Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma, Journal of Clinical Oncology, vol.23, issue.23, pp.5347-5356, 2005. ,
DOI : 10.1200/JCO.2005.13.466
Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma, Journal of Clinical Oncology, vol.27, issue.23, pp.3822-3829, 2009. ,
DOI : 10.1200/JCO.2008.20.7977
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas, Journal of Clinical Oncology, vol.17, issue.4, p.1244, 1999. ,
DOI : 10.1200/JCO.1999.17.4.1244
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML, Blood, vol.109, issue.8, pp.3509-3512, 2007. ,
DOI : 10.1182/blood-2006-06-030833
Antiangiogenic Potential of the Mammalian Target of Rapamycin Inhibitor Temsirolimus, Cancer Research, vol.66, issue.11, pp.5549-5554, 2006. ,
DOI : 10.1158/0008-5472.CAN-05-2825
Embolic pneumopathy induced by oleic acid. A systematic morphologic study, Am J Pathol, vol.87, pp.143-158, 1977. ,
Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF, Blood, vol.105, issue.11, pp.4463-4469, 2005. ,
DOI : 10.1182/blood-2004-09-3540
Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma, Journal of Hematology & Oncology, vol.3, issue.1, p.30, 2010. ,
DOI : 10.1186/1756-8722-3-30
URL : https://hal.archives-ouvertes.fr/inserm-00668207